Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12944913rdf:typepubmed:Citationlld:pubmed
pubmed-article:12944913lifeskim:mentionsumls-concept:C0085296lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0085828lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0162508lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0205107lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0040715lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C1171362lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C1522702lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0086860lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0162768lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0439852lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0599718lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0599813lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0599893lld:lifeskim
pubmed-article:12944913lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:12944913pubmed:issue36lld:pubmed
pubmed-article:12944913pubmed:dateCreated2003-8-28lld:pubmed
pubmed-article:12944913pubmed:abstractTextOverexpression of proto-oncogene c-jun and constitutive activation of the Jun N-terminal kinase (JNK) signaling pathway have been implicated in the leukemic transformation process. However, c-jun expression and the role of the JNK signaling pathway have not been investigated in primary acute myeloid leukemia (AML) cells with frequently observed balanced rearrangements such as t(8;21). In the present study, we report elevated c-jun mRNA expression in AML patient bone marrow cells with t(8;21), t(15;17) or inv(16), and a high correlation in mRNA expression levels of AML1-ETO and c-jun within t(8;21)-positive AML patient cells. In myeloid U937 cells, c-jun mRNA and protein expression increase upon inducible expression of AML1-ETO. AML1-ETO transactivates the human c-jun promoter through the proximal activator protein (AP-1) site by activating the JNK pathway. Overexpression of JNK-inhibitor JIP-1 and chemical JNK inhibitors reduce the transactivation capacity of AML1-ETO on the c-jun promoter and the proapoptotic function of AML1-ETO in U937 cells. An autocrine mechanism involving granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor (G-CSF-R) might participate in AML1-ETO mediated JNK-signaling, because AML1-ETO induces G-CSF and G-CSF-R expression, and G-CSF-R-neutralizing antibodies reduce AML1-ETO-induced JNK phosphorylation. These data suggest a model in which AML1-ETO induces proto-oncogene c-jun expression via the proximal AP-1 site of the c-jun promoter in a JNK-dependent manner.lld:pubmed
pubmed-article:12944913pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:languageenglld:pubmed
pubmed-article:12944913pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:citationSubsetIMlld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12944913pubmed:statusMEDLINElld:pubmed
pubmed-article:12944913pubmed:monthAuglld:pubmed
pubmed-article:12944913pubmed:issn0950-9232lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:ZhangDong-ErD...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:SchnittgerSus...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:SchochClaudia...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:TenenDaniel...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:HiddemannWolf...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:BehreGerhardGlld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:ReddyVenkates...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:KohlmannAlexa...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:FranzenMichae...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:UeffingMarius...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:ElsässerAnnik...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:WeisserMartin...lld:pubmed
pubmed-article:12944913pubmed:authorpubmed-author:BurelSebastia...lld:pubmed
pubmed-article:12944913pubmed:issnTypePrintlld:pubmed
pubmed-article:12944913pubmed:day28lld:pubmed
pubmed-article:12944913pubmed:volume22lld:pubmed
pubmed-article:12944913pubmed:ownerNLMlld:pubmed
pubmed-article:12944913pubmed:authorsCompleteYlld:pubmed
pubmed-article:12944913pubmed:pagination5646-57lld:pubmed
pubmed-article:12944913pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:meshHeadingpubmed-meshheading:12944913...lld:pubmed
pubmed-article:12944913pubmed:year2003lld:pubmed
pubmed-article:12944913pubmed:articleTitleThe fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.lld:pubmed
pubmed-article:12944913pubmed:affiliationDepartment of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University Munich, Germany.lld:pubmed
pubmed-article:12944913pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12944913pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12944913pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12944913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12944913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12944913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12944913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12944913lld:pubmed